As part of our ongoing series focussing on available medicines in Australia, we have added a product review of gemtuzumab ozogamicin in CD33+ acute myeloid leukaemia.
This review discusses pharmacological properties, mechanism of action and major studies featuring gemtuzumab ozogamicin. It also provides commentary and recommendations from Professor Jeff Szer, a member of the Clinical Haematology team at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital.
Please login below to download this issue (PDF)